LinkedIn

 آمار

تعداد نشریات20
تعداد شماره‌ها1,089
تعداد مقالات9,995
تعداد مشاهده مقاله26,315,061
تعداد دریافت فایل اصل مقاله7,269,937
Talebpoor, Maryam, Neshasteh-Riz, Ali, Koosha, Fereshteh, Eynali, Samira. (1401). The Application of ATR Kinase Inhibitor AZD6738 in Combination with Radiotherapy for the Treatment of Melanoma. سامانه مدیریت نشریات علمی, 12(3), 267-276. doi: 10.31661/jbpe.v0i0.1912-1000
Maryam Talebpoor; Ali Neshasteh-Riz; Fereshteh Koosha; Samira Eynali. "The Application of ATR Kinase Inhibitor AZD6738 in Combination with Radiotherapy for the Treatment of Melanoma". سامانه مدیریت نشریات علمی, 12, 3, 1401, 267-276. doi: 10.31661/jbpe.v0i0.1912-1000
Talebpoor, Maryam, Neshasteh-Riz, Ali, Koosha, Fereshteh, Eynali, Samira. (1401). 'The Application of ATR Kinase Inhibitor AZD6738 in Combination with Radiotherapy for the Treatment of Melanoma', سامانه مدیریت نشریات علمی, 12(3), pp. 267-276. doi: 10.31661/jbpe.v0i0.1912-1000
Talebpoor, Maryam, Neshasteh-Riz, Ali, Koosha, Fereshteh, Eynali, Samira. The Application of ATR Kinase Inhibitor AZD6738 in Combination with Radiotherapy for the Treatment of Melanoma. سامانه مدیریت نشریات علمی, 1401; 12(3): 267-276. doi: 10.31661/jbpe.v0i0.1912-1000

The Application of ATR Kinase Inhibitor AZD6738 in Combination with Radiotherapy for the Treatment of Melanoma

Journal of Biomedical Physics and Engineering
مقاله 6، دوره 12، شماره 3، مرداد و شهریور 2022، صفحه 267-276    اصل مقاله (849.27 K)
نوع مقاله: Original Research
شناسه دیجیتال (DOI): 10.31661/jbpe.v0i0.1912-1000
نویسندگان
Maryam Talebpoor1، 2؛ Ali Neshasteh-Riz* 3، 4؛ Fereshteh Koosha3، 5؛ Samira Eynali1
1MSc, Radiation Biology Research Center, Iran University of Medical Sciences, Tehran, Iran
2MSc, Department of Radiation Sciences, School of Paramedicine, Iran University of Medical Sciences, Tehran, Iran
3PhD, Radiation Biology Research Center, Iran University of Medical Sciences, Tehran, Iran
4PhD, Department of Radiation Sciences, School of Paramedicine, Iran University of Medical Sciences, Tehran, Iran
5PhD, Department of Radiology Technology, Faculty of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran
چکیده
Background: Melanoma is categorized as one of the most malignant, severe, and lethal cancers of the skin. Regarding the lack of efficiency of conventional therapies for most patients, novel therapeutic strategies are strongly required.
Objective: The current study aimed to assess the impact of AZD6738- an ATR kinase inhibitor- in combination with 6 MV X-ray on the human melanoma cell line (A375).
Material and Methods: In this experimental study, cells were treated with different concentrations of AZD6738 for 24 and 48 h in the presence and absence of radiation (2 Gy, 4 Gy, and 6 Gy). The cell viability and cell proliferation assay were examined in both experimental and control groups by MTT and colony formation techniques, respectively.
Results: The results indicated that by increasing the concentration of AZD6738, the cell viability was markedly diminished in all treatment groups. As expected, the cell viability of the cells treated with AZD6738 and radiation was significantly lower than the group treated with AZD6738 alone. Besides, the combinatory treatment significantly decreased cell proliferation in the melanoma cell line. The combination of AZD6738 with radiation resulted in a significant increase in cytotoxicity by a 50% increase in cell death when used at concentrations of 0.3 µM, 1 µM, 1.51 µM, and 1.61 µM, respectively.
Conclusion: The combination of AZD6738 with radiation possesses a synergistic effect on the reduction of the cell viability and proliferation of melanoma cells. This present study provides insight into the impact of Ataxia Telangiectasia and Rad3-related kinase (ATR) inhibition on the potential role of this kinase in the suppression of melanoma cell proliferation.
کلیدواژه‌ها
AZD6738؛ Melanoma؛ Radiotherapy؛ Cell Proliferation
سایر فایل های مرتبط با مقاله
مراجع
  1. Mendenhall WM, Riggs CE, Vaysberg M, Amdur RJ, Werning JW. Altered fractionation and adjuvant chemotherapy for head and neck squamous cell carcinoma. Head & Neck. 2010;32(7):939-45. doi: 10.1002/hed.21261. PubMed PMID: 19894219.
  2. Thayaparasingham B, Kunz A, Peters N, Kulms D. Sensitization of melanoma cells to TRAIL by UVB-induced and NF-κB-mediated downregulation of xIAP. 2009;28(3):345-62. doi: 10.1038/onc.2008.397. PubMed PMID: 18978816.
  3. Lasithiotakis KG, Leiter U, Gorkievicz R, Eigentler T, et al. The incidence and mortality of cutaneous melanoma in Southern Germany: trends by anatomic site and pathologic characteristics, 1976 to 2003. Cancer. 2006;107(6):1331-9. doi: 10.1002/cncr.22126. PubMed PMID: 16909413.
  4. Jahng AW, Liao SS. Successful palliation with octreotide of a neuroendocrine syndrome from malignant melanoma. J Pain Symptom Manage. 2006;32(2):191-5. doi: 10.1016/j.jpainsymman.2006.02.014. PubMed PMID: 16877188.
  5. Chen W, Lu Y, Wu J, Gao M, Wang A, Xu B. Beta-elemene inhibits melanoma growth and metastasis via suppressing vascular endothelial growth factor-mediated angiogenesis. Cancer Chemotherapy and Pharmacology. 2011;67(4):799-808. doi: 10.1007/s00280-010-1378-x. PubMed PMID: 20563582.
  6. De Almodovar JR, Nunez MI, McMillan TJ, Olea N, et al. Initial radiation-induced DNA damage in human tumour cell lines: a correlation with intrinsic cellular radiosensitivity. Br J Cancer. 1994;69(3):457-62. doi: 10.1038/bjc.1994.83. PubMed PMID: 8123473. PubMed PMCID: PMC1968865.
  7. Khan MK, Khan N, Almasan A, Macklis R. Future of radiation therapy for malignant melanoma in an era of newer, more effective biological agents. Onco Targets Ther. 2011;4:137-48. doi: 10.2147/OTT.S20257. PubMed PMID: 21949607. PubMed PMCID: PMC3176173.
  8. Grossmann KF, Margolin K. Long-term survival as a treatment benchmark in melanoma: latest results and clinical implications. Ther Adv Med Oncol. 2015;7(3):181-91. doi: 10.1177/1758834015572284. PubMed PMID: 26673806. PubMed PMCID: PMC4406913.
  9. Balavandi Z, Neshasteh-Riz A, Koosha F, et al. The Use of ß-Elemene to Enhance Radio Sensitization of A375 Human Melanoma Cells. Cell J. 2020;21(4):419-25. doi: 10.22074/cellj.2020.6326. PubMed PMID: 31376323. PubMed PMCID: PMC6722453.
  10. Gilbert J, Forastiere AA. Organ preservation trials for laryngeal cancer. Otolaryngologic Clinics of North America. 2002;35(5):1035-54. doi: 10.1016/s0030-6665(02)00035-x. PubMed PMID: 12587246.
  11. Kumala S, Niemiec P, Wideł M, Hancock R, Rzeszowska-Wolny J. Apoptosis and clonogenic survival in three tumour cell lines exposed to gamma rays or chemical genotoxic agents. Cell Mol Biol Lett. 2003;8(3):655-65. PubMed PMID: 12949606.
  12. Morton DL, Wen DR, Wong JH, Economou JS, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Archives of Surgery. 1992;127(4):392-9. doi: 10.1001/archsurg.1992.01420040034005. PubMed PMID: 1558490.
  13. Garbe C, Hauschild A, Volkenandt M, Schadendorf D, et al. Evidence and interdisciplinary consensus-based German guidelines: surgical treatment and radiotherapy of melanoma. Melanoma Research. 2008;18(1):61-7. doi: 10.1097/CMR.0b013e3282f0c893. PubMed PMID: 18227710.
  14. Gershenwald JE, Thompson W, Mansfield PF, Lee JE, et al. Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol. 1999;17(3):976-83. doi: 10.1200/JCO.1999.17.3.976. PubMed PMID: 10071292.
  15. Morton DL, Thompson JF, Cochran AJ, Mozzillo N, et al. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med. 2006;355(13):1307-17. doi: 10.1056/NEJMoa060992. PubMed PMID: 17005948.
  16. Garbe C, Terheyden P, Keilholz U, Kölbl O, Hauschild A. Treatment of melanoma. Dtsch Arztebl Int. 2008;105(49):845-51. doi: 10.3238/arztebl.2008.0845. PubMed PMID: 19561811. PubMed PMCID: PMC2689638.
  17. Gaudi S, Messina JL. Molecular bases of cutaneous and uveal melanomas. Patholog Res Int. 2011:1-8. doi: 10.4061/2011/159421. PubMed PMID: 21876842. PubMed PMCID: PMC3159309.
  18. Shi H, Liu L, Liu L, Geng J, Zhou Y, Chen L. β-Elemene inhibits the metastasis of B16F10 melanoma cells by downregulation of the expression of uPA, uPAR, MMP-2, and MMP-9. Melanoma Res. 2014;24(2):99-107. doi: 10.1097/CMR.0000000000000043. PubMed PMID: 24535052.
  19. Ghazikhanlou-Sani K, Rahimi A, Poorkaveh M, et al. Evaluation of the electromagnetic field intensity in operating rooms and estimation of occupational exposures of personnel. Interventional Medicine and Applied Science. 2018;10(3):121-6. doi: 10.1556/1646.10.2018.18. PubMed PMID: 30713749. PubMed PMCID: PMC6343582.
  20. Karnitz LM, Zou L. Molecular pathways: targeting ATR in cancer therapy. Clin Cancer Res. 2015;21(21):4780-5. doi: 10.1158/1078-0432.CCR-15-0479. PubMed PMID: 26362996. PubMed PMCID: PMC4631635.
  21. Brown EJ, Baltimore D. ATR disruption leads to chromosomal fragmentation and early embryonic lethality. Genes & Development. 2000;14(4):397-402. PubMed PMID: 10691732. PubMed PMCID: PMC316378.
  22. Takai H, Tominaga K, Motoyama N, Minamishima YA, et al. Aberrant cell cycle checkpoint function and early embryonic death in Chk1−/− mice. Genes & Development. 2000;14(12):1439-47. PubMed PMID: 10859163. PubMed PMCID: PMC316691.
  23. Zou L, Elledge SJ. Sensing DNA damage through ATRIP recognition of RPA-ssDNA complexes. Science. 2003;300(5625):1542-8. doi: 10.1126/science.1083430. PubMed PMID: 12791985.
  24. Ruzankina Y, Pinzon-Guzman C, Asare A, Ong T, Pontano L, et al. Deletion of the developmentally essential gene ATR in adult mice leads to age-related phenotypes and stem cell loss. Cell Stem Cell. 2007;1(1):113-26. doi: 10.1016/j.stem.2007.03.002. PubMed PMID: 18371340. PubMed PMCID: PMC2920603.
  25. Eykelenboom JK, Harte EC, Canavan L, Pastor-Peidro A, et al. ATR activates the SM checkpoint during unperturbed growth to ensure sufficient replication prior to mitotic onset. Cell Reports. 2013;5(4):1095-107. doi: 10.1016/j.celrep.2013.10.027. PubMed PMID: 24268773.
  26. Kim HJ, Min A, Im SA, Jang H, Lee KH, Lau A, et al. Anti-tumor activity of the ATR inhibitor AZD6738 in HER2 positive breast cancer cells. International Journal of Cancer. 2017;140(1):109-19. doi: 10.1002/ijc.30373. PubMed PMID: 27501113.
  27. Pires IM, Olcina MM, Anbalagan S, Pollard JR, et al. Targeting radiation-resistant hypoxic tumour cells through ATR inhibition. British Journal of Cancer. 2012;107(2):291-9. doi: 10.1038/bjc.2012.265. PubMed PMID: 22713662. PubMed PMCID: PMC3394988.
  28. Hammond EM, Denko NC, Dorie MJ, Abraham RT, Giaccia AJ. Hypoxia links ATR and p53 through replication arrest. Molecular and Cellular Biology. 2002;22(6):1834-43. PubMed PMID: 11865061. PubMed PMCID: PMC135616.
  29. Hammond EM, Dorie MJ, Giaccia AJ. Inhibition of ATR leads to increased sensitivity to hypoxia/reoxygenation. Cancer Research. 2004;64(18):6556-62. doi: 10.1158/0008-5472.CAN-04-1520. PubMed PMID: 15374968.
  30. Zhou ZW, Liu C, Li TL, Bruhn C, Krueger A, Min W, Wang ZQ, Carr AM. An essential function for the ATR-activation-domain (AAD) of TopBP1 in mouse development and cellular senescence. PLoS Genetics. 2013;9(8):e1003702. doi: 10.1371/journal.pgen.1003702. PubMed PMID: 23950734. PubMed PMCID: PMC3738440.
  31. Demidenko ZN, Blagosklonny MV. Flavopiridol induces p53 via initial inhibition of Mdm2 and p21 and, independently of p53, sensitizes apoptosis-reluctant cells to tumor necrosis factor. Cancer Research. 2004;64(10):3653-60. doi: 10.1158/0008-5472.CAN-04-0204. PubMed PMID: 15150125.
  32. Murga M, Campaner S, Lopez-Contreras AJ, Toledo LI, et al. Exploiting oncogene-induced replicative stress for the selective killing of Myc-driven tumors. Nature Structural & Molecular Biology. 2011;18(12):1331-5. doi: 10.1038/nsmb.2189. PubMed PMID: 22120667. PubMed PMCID: PMC4894468.
  33. Dillon MT, Barker HE, Pedersen M, Hafsi H, Bhide SA, et al. Radiosensitization by the ATR inhibitor AZD6738 through generation of acentric micronuclei. Molecular Cancer Therapeutics. 2017;16(1):25-34. doi: 10.1158/1535-7163.MCT-16-0239.
  34. Foote KM, Lau A, M Nissink JW. Drugging ATR: progress in the development of specific inhibitors for the treatment of cancer. Future Medicinal Chemistry. 2015;7(7):873-91. doi: 10.4155/fmc.15.33. PubMed PMID: 26061106.
  35. Checkley S, MacCallum L, Yates J, Jasper P, Luo H, Tolsma J, Bendtsen C. Bridging the gap between in vitro and in vivo: dose and schedule predictions for the ATR inhibitor AZD6738. Scientific Reports. 2015;5:13545. doi: 10.1038/srep13545. PubMed PMID: 26310312. PubMed PMCID: PMC4550834.
  36. Vendetti FP, Lau A, Schamus S, Conrads TP, O’Connor MJ, Bakkenist CJ. The orally active and bioavailable ATR kinase inhibitor AZD6738 potentiates the anti-tumor effects of cisplatin to resolve ATM-deficient non-small cell lung cancer in vivo. Oncotarget. 2015;6(42):44289. doi: 10.18632/oncotarget.6247. PubMed PMID: 26517239. PubMed PMCID: PMC4792557.
  37. Clack G, Lau A, Pierce A, Smith S, Stephens C. O6. 3 ATR inhibitor AZD6738. Annals of Oncology. 2015;26(suppl 2):ii8. doi: 10.1093/annonc/mdv084.3.
  38. Min A, Im SA, Jang H, Kim S, Lee M, et al. Abstract LB-107: Targeting ATR using a novel ATR inhibitor AZD6738 in human gastric cancer cells. Cancer Research. 2015;75(15). doi: 10.1158/1538-7445.AM2015-LB-107.
آمار
تعداد مشاهده مقاله: 2,035
تعداد دریافت فایل اصل مقاله: 432


سامانه مدیریت نشریات علمی. قدرت گرفته از سیناوب